GlassScriptPhysician profile
Aleicia R Mack
NPI 1629105879
$4,838.09
in general payments reported to CMS, 2019-2025
24 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $299 · 2021: $493 · 2022: $919 · 2023: $909 · 2024: $1,062 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,518.42 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $872.89 | 2019-2025 | |
| Amgen INC. | $307.31 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.19 | 2019-2024 | Jardiance |
| Pfizer INC. | $281.77 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $250.61 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $207.79 | 2019-2022 | |
| Novo Nordisk INC | $178.63 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $142.25 | 2023-2025 | Onpattro |
| Kestra Medical Technology Services, INC. | $121.72 | 2023-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $111.96 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $89.66 | 2024 | Arcalyst |
| Philips North America LLC | $58.29 | 2024 | (Ck4) Mcot |
| Amarin Pharma, INC. | $57.68 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $54.47 | 2021-2023 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.70 | 2022-2024 | Mitraclip |
| Atricure, INC. | $50.82 | 2022-2024 | |
| Boston Scientific Corporation | $42.00 | 2022-2025 | Watchman Flx |
| Irhythm Technologies, INC. | $30.71 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $24.62 | 2025 | Barostim Neo System |
| Althera Pharmaceuticals LLC | $20.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.20 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.74 | 2024 | |
| Lilly USA, LLC | $15.09 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleicia Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.